Disclosures

1. Why this page exists

The longevity, wellness, and supplement industries run on financial incentives that are mostly invisible to readers. A “research review” might be sponsored. A “protocol” might be a funnel into a supplement line. A “clinician” on a podcast might own equity in the company they're recommending. Calibrated Signal exists in part because the editor spent fifteen years inside that industry and watched how those incentives shape what gets said, sold, and believed.

This page is an attempt to make our own incentives fully legible. The standard we hold ourselves to is the standard we'd want from any publication we'd trust on these topics — comparable to what Eric Topol, Roger Seheult, and Gil Carvalho publish about their own disclosures.

2. What we accept

• Affiliate commissions for a narrow set of non-supplement products. Diagnostics and lab testing (for example, Function Health, blood-test services, lipoprotein testing), wearables and biometrics (Eight Sleep, Levels, Whoop, Oura, blood-pressure monitors), and books that the editor recommends. These categories share a property: the product is a tool that generates information for you, not a product whose value depends on someone interpreting it for you.
• Subscription revenue. Calibrated Signal will offer paid memberships that fund the publication directly from readers. Subscription is the long-term funding model; affiliate revenue is a bridge.
• Speaking fees from academic, medical, and scientific institutions. Speaking fees, honoraria, and travel reimbursement for talks at universities, medical conferences, research institutes, and non-profit educational organizations.
• Sample products for testing. Companies occasionally send us hardware (wearables, monitors) or services (lab tests) to evaluate. Receipt of a sample does not commit us to coverage. If we cover it, the sample is disclosed inline on that article.

3. What we will not accept

• Affiliate commissions from supplement companies. Period.No multivitamins, no NAD precursors, no rapamycin analogs, no nootropic stacks, no greens powders. Whether or not a supplement is “evidence-based,” the structural conflict between getting paid when readers buy it and writing honestly about whether the evidence supports it is a line we will not cross.
• A Calibrated Signal supplement line. No now, no later, no rebranded white-label products, no joint-venture brand. Selling supplements while writing critically about supplements is the conflict the publication exists to model the alternative to.
• Sponsored content, native advertising, or paid placements of any kind.No “sponsored by” posts, no “in partnership with” articles, no paid newsletter inserts. Every article is written for editorial reasons, not for revenue.
• Equity stakes in covered companies. The editor does not hold equity, options, or convertible instruments in any supplement, diagnostic, wearable, pharmaceutical, or wellness company that may be covered on the Site.
• Exclusive single-brand endorsements.When we cover a category, we cover the category — not a preferred brand within it.
• Affiliate links for products we haven't personally used or evaluated. If we link to it, the editor has used it or read the underlying evidence for it.

4. How disclosure works on individual articles

We follow the FTC Endorsement Guides (16 CFR Part 255, revised 2023, actively enforced through 2026). Articles that contain affiliate links carry:

• A disclosure banner at the top of the article (before the first affiliate link, above the fold) that states: “This article contains affiliate links. If you click through and purchase, we may earn a commission at no additional cost to you. We only link to products we've personally used or evaluated, and we do not accept payment for coverage.”
• An inline disclosurenext to each affiliate link itself, so that the disclosure is visible at the moment of the link — not buried in a footer.
• A per-link redirect through calibratedsignal.com/go/[slug] so that affiliate links resolve through our own domain. This lets us track which links readers click without sharing click data with affiliate networks beyond what those networks need to attribute the sale, and it makes broken-link cleanup mechanical.

5. The conflict-of-interest disclosure

From the late 2000s through the early 2020s, Nick was the CEO of a large international supplement and functional-beverage company. The company nearly went public, appeared on Shark Tank, and won Forbes business awards. Nick left the supplement industry, no longer holds equity or advisory positions in any supplement, wellness, diagnostic, or pharmaceutical company, and does not receive ongoing compensation from any company in those categories.

This history is the most important disclosure on this page. The reason Calibrated Signal exists, and the reason its policies on supplement money are as strict as they are, is that the editor spent fifteen years watching how industry incentives shape what readers are told. “Honest broker” is not branding — it is a deliberate response to what he saw from the inside.

6. Dissertation funding

Nick's doctoral dissertation work (the bioinformatics pipeline mapping longevity interventions to the hallmarks of aging, which is the foundation of the sister project at calibratedage.com) is entirely self-funded. There is no university research grant, no industry funding, no pharmaceutical or supplement company support, and no partnership with any commercial entity.

7. Reader-flagged disclosures

If you spot an undisclosed conflict of interest in any article on the Site, please email disclosures@calibratedsignal.com with the article and what you believe should be disclosed. Verified disclosures are added to the article within 24 hours, with credit to the reader who flagged it (with permission).

8. Annual transparency log

Once per year, Calibrated Signal will publish a transparency log itemizing: affiliate programs participated in, total affiliate revenue by category, speaking fees received, institutional honoraria, sample products received for testing, and any sponsorship or partnership requests declined. The first log will be published at the end of 2026.

9. Related pages

For privacy practices see Privacy Policy. For medical scope and the line between editorial coverage and clinical advice see Medical Disclaimer. For how factual errors are corrected see Corrections.